NCT07849101Not yet recruiting
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
Multicenter, Prospective, Randomized, Open-Label, Controlled, Two-Arm, Parallel-Group, Superiority Clinical Investigation on the Use of Ceramol PSOR Cream in Patients With Mild-to-Moderate Plaque Psoriasis Treated With Narrowband UVB Phototherapy: CERAMOL PSOR CREMA Study
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This is a multicenter, prospective, randomized, open-label, controlled clinical investigation to evaluate whether Ceramol PSOR cream, used as an adjuvant treatment, is superior to a comparator emollient cream in patients with mild-to-moderate plaque psoriasis undergoing narrowband UVB phototherapy. Participants apply the assigned cream topically once daily throughout one standard phototherapy cycle (36 ± 3 UVB sessions). The study assesses clinical response (PASI, body surface area), subjective symptoms (pruritus and dryness/tightness VAS), quality of life (DLQI), treatment satisfaction, and adherence to both the investigational product and phototherapy.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 17 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- Unifarco SpA
- Diseases
- Psoriasis
- NCT number
- NCT07849101
What you commit to
- Study type: Interventional
- Planned participants: 128
- From Oct 2026 to the primary completion date, Jun 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving systemic pharmacological treatment for psoriasis.
- Patients receiving topical pharmacological treatment for psoriasis, or who discontinued such treatment less than one (1) week before enrollment.
Other illness
- Any active dermatological condition unrelated to psoriasis that could interfere with study results.
- Cognitive impairment preventing completion of the study questionnaires.
Who the study is looking for
- Age ≥ 18 years.
- Clinical diagnosis of mild or moderate plaque psoriasis.
- Body surface area (BSA) involvement of 3-10%, excluding palms and soles.
- Planned treatment with narrowband UVB phototherapy as part of routine clinical practice.
- Presence of at least one psoriasis-associated symptom (pruritus/burning, dryness/tightness) with a VAS score ≥ 3 at study entry.
- Ability to understand and sign the Informed Consent Form
- Willingness to use only the study product as the daily body moisturizer during the phototherapy cycle.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario de la Princesa Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario Puerta de Hierro - Majadahonda Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.